
zzso zzso zzso was evaluated in a zzso zzso controlled study for the treatment of localized zzso zzso zzso was administered zzso in a dose of 50 zzso body surface area once daily for 4 days, always within 14 days of onset of the first symptom and usually within 7 zzso Thirty patients given zzso and 30 patients given zzso were well matched with respect to age, sex, and length and severity of presenting rash and pain as well as underlying zzso There was no difference in the rate of disappearance of pain or rash in either treatment zzso More patients given zzso than patients given zzso had minimal pain and significantly more zzso patients had persistence of neurological symptoms at 6 months' zzso Acute side effects, though mild, were significantly increased in the zzso patients especially with respect to zzso and vomiting and decrease in zzso zzso zzso administered in this dose zzso had no beneficial effect and was associated with mild side effects and persistence of neurological zzso 

